Colon Cancer
Colon cancer treatment is guided by RAS, BRAF, MSI-H, and HER2 status, which determine eligibility for anti-EGFR antibodies, BRAF-targeted combinations, immunotherapy, and novel ADC-based approaches in metastatic disease. Liver-limited metastatic disease may be eligible for curative resection with appropriate systemic management. CancerFax helps patients access molecular-guided systemic therapy, liver surgery programs, and specialist colorectal oncology review.
- RAS, BRAF, MSI-H & colon cancer molecular profiling
- Anti-EGFR, BRAF combo, IO & liver-directed therapy
- Metastatic colon cancer specialist & trial access
- New Cases Annually (US)
- ~107,320
- Most Common Type
- Adenocarcinoma
- Key Diagnostic
- Colonoscopy + Biopsy
- Curative Rate (Early)
- ~90% Stage I
- Median Age
- >50 years
What is Colon Cancer
Types and Subtypes
Colon cancer is classified by histologic type, stage, and molecular characteristics. These classifications determine treatment approach and prognosis.
Symptoms and Signs
Many people with early-stage colon cancer have no symptoms. Polyps and early cancers often do not cause noticeable signs. This is why screening is so important. When symptoms do develop, they typically reflect the location and size of the cancer.
Causes and Risk Factors
The exact cause of colon cancer is not fully understood, but it results from accumulated genetic mutations in colon cells. Multiple risk factors increase the likelihood of developing these mutations and subsequently colon cancer.
Diagnosis and Investigations
Diagnosis of colon cancer involves a combination of clinical evaluation, screening tests, imaging, and pathologic examination. Early detection through screening significantly improves outcomes.
Disease Staging and Risk Stratification
Colon cancer staging uses the TNM (Tumor, Node, Metastasis) system. Stage is the most important prognostic factor and guides treatment decisions.
Standard Treatment Options
Treatment for colon cancer is multimodal and depends on stage, molecular characteristics, and patient factors. The goal is cure for early-stage disease and control/palliation for advanced disease.
Advanced & Emerging Therapies
For patients with advanced or metastatic colon cancer, or those with recurrent disease, access to advanced therapies through clinical trials and specialized centers is increasingly important. Multiple novel approaches targeting specific molecular alterations are in development.
Anti-EGFR Monoclonal Antibody
Cetuximab, Panitumumab
Targeted therapy for KRAS wild-type tumors. Blocks epidermal growth factor receptor signaling. Used in combination with chemotherapy for metastatic disease.
Anti-VEGF Monoclonal Antibody
Bevacizumab
Blocks vascular endothelial growth factor to inhibit tumor angiogenesis. Used in combination with chemotherapy for metastatic disease.
Anti-VEGF Receptor Tyrosine Kinase Inhibitor
Aflibercept, Ramucirumab
Alternative anti-angiogenic agents used in combination with chemotherapy for metastatic disease, particularly in second-line settings.
Checkpoint Immunotherapy
Pembrolizumab, Nivolumab
PD-1 checkpoint inhibitors for MSI-H or mismatch repair-deficient tumors. Increasingly used as first-line therapy for metastatic MSI-H disease.
Multikinase Inhibitor
Regorafenib, TAS-102
Targeted therapies for refractory metastatic disease that has progressed on standard chemotherapy and targeted therapy.
HER2-Targeted Therapy
Trastuzumab + Pertuzumab
For rare HER2-amplified colon cancers. Dual HER2 blockade combined with chemotherapy.
BRAF-Targeted Therapy
Encorafenib + Cetuximab
For BRAF-mutant colon cancers. BRAF inhibitor combined with anti-EGFR therapy.
Combination Immunotherapy
Nivolumab + Ipilimumab
Dual checkpoint inhibition for MSI-H tumors; emerging as potentially superior to single-agent immunotherapy.
Biomarkers & Precision Medicine
Molecular profiling is essential in colon cancer for treatment selection, predicting therapy response, and identifying patients who may benefit from targeted or immune-based approaches.
When to Seek a Second Opinion
Expert review of pathology, staging, and treatment recommendations can significantly impact outcomes. Second opinion is particularly valuable in complex or advanced cases.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis for colon cancer depends on stage at diagnosis, molecular characteristics, histologic grade, and treatment response. Early detection through screening significantly improves outcomes.
Supportive Care & Living With Colon Cancer
Supportive care is an essential component of colon cancer treatment, addressing both the physical and emotional impacts of the disease and its treatment.
How CancerFax Helps You Explore Treatment Options
How can CancerFax help patients with colon cancer? Our organization helps patients with colon cancer by ensuring that there is a coordinated evaluation of pathology and molecular testing for correct diagnoses and stages of the disease. We link our clients with specialist colorectal surgeons and medical oncologists and ensure that our patients get the benefits of chemotherapy, targeted, and immunotherapy treatments.
Get a free case reviewFrequently Asked Questions
Colon cancer is a malignant growth of cells that begins in the colon, the first and longest part of the large intestine. It is the third most common cancer worldwide and typically develops from benign polyps over 10-15 years.
Colon cancer begins in the colon, while rectal cancer begins in the rectum (the last part of the large intestine). They are often grouped together as colorectal cancer but may have slightly different treatment approaches due to anatomic differences.
Screening methods include colonoscopy (gold standard), flexible sigmoidoscopy, fecal immunochemical test (FIT), fecal occult blood test (FOBT), and CT colonography. Screening is recommended for all adults aged 50 and older (or age 45 for African Americans).
Colon cancer is staged from 0 to IV using the TNM system. Stage 0 is confined to the mucosa, Stage I invades submucosa/muscularis, Stage II invades through muscularis without lymph node involvement, Stage III involves regional lymph nodes, and Stage IV involves distant metastases.
Molecular testing identifies microsatellite instability (MSI), KRAS mutations, BRAF mutations, and other markers. These guide treatment selection: MSI-H tumors benefit from immunotherapy, KRAS wild-type tumors benefit from anti-EGFR therapy, and BRAF-mutant tumors may benefit from BRAF inhibitors.
Treatment depends on stage. Stage 0-I: surgery alone. Stage II: surgery with consideration of adjuvant chemotherapy for high-risk features. Stage III: surgery plus adjuvant chemotherapy (FOLFOX or CAPOX). Stage IV: surgery for resectable metastases plus chemotherapy, or systemic chemotherapy with targeted/immune therapy for unresectable disease.
Adjuvant chemotherapy is chemotherapy given after surgery to reduce the risk of cancer recurrence. It is standard for Stage III colon cancer and considered for high-risk Stage II disease. FOLFOX and CAPOX are common regimens.
Targeted therapies include anti-EGFR agents (cetuximab, panitumumab for KRAS wild-type), anti-VEGF agents (bevacizumab, aflibercept, ramucirumab), BRAF inhibitors (encorafenib for BRAF-mutant), and HER2-targeted therapy (trastuzumab + pertuzumab for HER2-amplified tumors).
Yes. CancerFax helps patients with colon cancer by coordinating expert pathology and molecular review to ensure accurate diagnosis and staging. We connect patients with specialist colorectal surgeons and medical oncologists, facilitate access to chemotherapy, targeted therapy, and immunotherapy options, and provide guidance on surgical approaches and international treatment coordination at major centers globally, including specialized institutions in China.